News
Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.
DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
‘We will work collaboratively’: Big Pharma admits it is discussing Trump’s plan to lower drug prices
Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Squibb Coffee's new European-inspired cafe brings wine, cheese, small plates and coffee together in one space.
Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI ...
Tariff risks remain high for July CPI. A higher CPI print increases the likelihood of a Fed rate cut. Check out the expected ...
The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...
Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...
In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.
The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results